Diabetic cardiac autonomic neuropathy deterioration

1. Inflammation mediates diabetic cardiac autonomic neuropathy deterioration in humans (12.9%).

   Humansbetween HbA1c and DCAN progressionn = 293

   SGLT2 inhibition, uric acid and inflammation in glycemic burden-related progression of cardiac autonomic neuropathy in type 2 diabetes mellitus: insights from machine learning and mediation analysis

   Frontiers in endocrinology·5 Aug 2026

More on Inflammation

1. Purine metabolism mediates diabetic cardiac autonomic neuropathy deterioration in humans (20.6%).

   Humansbetween HbA1c and DCAN progressionn = 293

   SGLT2 inhibition, uric acid and inflammation in glycemic burden-related progression of cardiac autonomic neuropathy in type 2 diabetes mellitus: insights from machine learning and mediation analysis

   Frontiers in endocrinology·5 Aug 2026

More on Purine metabolism

1. HbA1c raises the risk of diabetic cardiac autonomic neuropathy deterioration in humans.

   Humansin patients with type 2 diabetes mellitusn = 293

   SGLT2 inhibition, uric acid and inflammation in glycemic burden-related progression of cardiac autonomic neuropathy in type 2 diabetes mellitus: insights from machine learning and mediation analysis

   Frontiers in endocrinology·5 Aug 2026

More on HbA1c

1. SGLT2 inhibitors lower the risk of diabetic cardiac autonomic neuropathy deterioration in humans.

   Humansin patients with type 2 diabetes mellitusn = 293

   SGLT2 inhibition, uric acid and inflammation in glycemic burden-related progression of cardiac autonomic neuropathy in type 2 diabetes mellitus: insights from machine learning and mediation analysis

   Frontiers in endocrinology·5 Aug 2026

More on SGLT2 inhibitors